Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
461 to 480 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Host Immune Regulation in Implant-Associated Infection (IAI): What Does the Current Evidence Provide Us to Prevent or Treat IAI? | Bioengineering (Basel) | 2023 | 36978747 | PubTator, text mining | PubMed |
| Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. | Front Immunol | 2023 | 36969235 | PubTator, text mining | PubMed |
| An inflammation-related gene landscape predicts prognosis and response to immunotherapy in virus-associated hepatocellular carcinoma. | Front Oncol | 2023 | 36969014 | PubTator, text mining | PubMed |
| Primary Langerhans cell sarcoma in the urinary bladder: Case report and literature review. | Front Oncol | 2023 | 36968999 | PubTator, text mining | PubMed |
| Development and validation of focal adhesion-related genes signature in gastric cancer. | Front Genet | 2023 | 36968601 | PubTator, text mining | PubMed |
| Identification of Prognostic Biomarkers for Breast Cancer Metastasis Using Penalized Additive Hazards Regression Model. | Cancer Inform | 2023 | 36968522 | PubTator, text mining | PubMed |
| Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment. | Front Immunol | 2023 | 36960055 | PubTator, text mining | PubMed |
| Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses. | Heliyon | 2023 | 36950599 | PubTator, text mining | PubMed |
| Autophagy-related gene LAPTM4B promotes the progression of renal clear cell carcinoma and is associated with immunity. | Front Pharmacol | 2023 | 36937841 | PubTator, text mining | PubMed |
| Characterization of immature ovarian teratomas through single-cell transcriptome. | Front Immunol | 2023 | 36936909 | PubTator, text mining | PubMed |
| Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network. | Sci Rep | 2023 | 36922519 | PubTator, text mining | PubMed |
| Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets. | Aging (Albany NY) | 2023 | 36920183 | PubTator, text mining | PubMed |
| Elevated NDC1 expression predicts poor prognosis and correlates with immunity in hepatocellular carcinoma. | J Gastrointest Oncol | 2023 | 36915467 | PubTator, text mining | PubMed |
| Comprehensive analysis of cuproptosis-related long noncoding RNA for predicting prognostic and diagnostic value and immune landscape in colorectal adenocarcinoma. | Hum Genomics | 2023 | 36915193 | PubTator, text mining | PubMed |
| Lipid metabolism-related miRNAs with potential diagnostic roles in prostate cancer. | Lipids Health Dis | 2023 | 36915125 | PubTator, text mining | PubMed |
| A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer. | Front Genet | 2023 | 36911392 | PubTator, text mining | PubMed |
| Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC. | Front Oncol | 2023 | 36910653 | PubTator, text mining | PubMed |
| MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer. | Transl Oncol | 2023 | 36907052 | PubTator, text mining | PubMed |
| Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer. | Int J Mol Sci | 2023 | 36901944 | PubTator, text mining | PubMed |
| Prognostic Value of EMT Gene Signature in Malignant Mesothelioma. | Int J Mol Sci | 2023 | 36901697 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=24